Cinacalcet and primary hyperparathyroidism: systematic review and meta regression

摘要: Purpose Primary hyperparathyroidism (PHPT) is a common condition affecting people of all ages and mainly treated with parathyroidectomy. Cinacalcet has been widely used in secondary or tertiary hyperparathyroidism, but the use cinacalcet PHPT less clear. Methods Searches were conducted Medline Embase for from induction to 10 April 2020. Articles conferences abstracts describing prospective retrospective cohorts randomized controlled trials restricted English language only. We initially identified 1301 abstracts. Each article went extraction by two blinded authors on structured proforma. Continuous outcomes pooled weight mean difference (WMD). Quality included articles was assessed Newcastle Ottwa Scale Cochrane Risk Bias 2.0. Results Twenty-eight included. Normalization rate serum Ca levels reported at 90% (CI: 0.82 0.96). Serum PTH significantly reduced (Ca, WMD: 1.647, CI: -1.922 -1.371; PTH, -31.218, -41.671 -20.765) phosphate increased (WMD: 0.498, 0.400 0.596) after therapy. The higher baseline levels, greater reduction treatment. Age gender did not modify effect levels. Conclusion results meta-analysis support as an alternative bridging therapy treat hypercalcemia PHPT.